Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/11/2024 | $35.00 | Overweight | KeyBanc Capital Markets |
| 8/9/2024 | $28.00 → $33.00 | Hold → Buy | Truist |
| 4/22/2024 | $40.00 | Buy | Citigroup |
| 3/1/2024 | $45.00 | Outperform | Oppenheimer |
| 1/3/2024 | $39.00 | Overweight | Barclays |
| 12/6/2023 | $37.00 | Mkt Outperform | JMP Securities |
| 10/16/2023 | $46.00 | Buy | UBS |
| 4/12/2023 | $40.00 | Overweight | Stephens |
8-K - Evolent Health, Inc. (0001628908) (Filer)
8-K - Evolent Health, Inc. (0001628908) (Filer)
8-K - Evolent Health, Inc. (0001628908) (Filer)
KeyBanc Capital Markets initiated coverage of Evolent Health with a rating of Overweight and set a new price target of $35.00
Truist upgraded Evolent Health from Hold to Buy and set a new price target of $33.00 from $28.00 previously
Citigroup initiated coverage of Evolent Health with a rating of Buy and set a new price target of $40.00
The former Fortune 50 CEO joins Define to further drive transformational change in healthcare at the earliest stages of innovation SAN FRANCISCO, Oct. 22, 2024 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Bruce Broussard, former CEO and president of Humana (NYSE:HUM), has joined the firm as venture partner. Bruce will play a pivotal role at Define, leveraging his invaluable experience scaling companies and fostering innovation within private startups, mid-size companies, and the Fortune 50. He will partner closely with Define founders to scale their businesses and become category-defining companie
Company to Participate in Upcoming Conferences WASHINGTON, Oct. 11, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9
Revenue of $647.1 million, an increase of $178.0 million or 37.9%, from the three months ended June 30, 2023.Net loss attributable to common shareholders of Evolent Health, Inc. of $(6.4) million and a net loss margin of (1.0)%.Adjusted EBITDA of $52.0 million resulting in an Adjusted EBITDA margin of 8.0%.Narrows revenue outlook for full year 2024 and provides updated 2024 Adjusted EBITDA guidance.Reiterates confidence in achieving $300 million in Adjusted EBITDA run rate exiting 2024.WASHINGTON, Aug. 8, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care
SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)
SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)
SC 13G - Evolent Health, Inc. (0001628908) (Subject)
The former Fortune 50 CEO joins Define to further drive transformational change in healthcare at the earliest stages of innovation SAN FRANCISCO, Oct. 22, 2024 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Bruce Broussard, former CEO and president of Humana (NYSE:HUM), has joined the firm as venture partner. Bruce will play a pivotal role at Define, leveraging his invaluable experience scaling companies and fostering innovation within private startups, mid-size companies, and the Fortune 50. He will partner closely with Define founders to scale their businesses and become category-defining companie
WASHINGTON, Dec. 1, 2021 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent"), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced that Seth R. Frank has joined the company as Vice President, Investor Relations, effective immediately. Reporting to John Johnson, Evolent's Chief Financial Officer, Seth will lead Evolent's investor relations (IR) strategy and oversee its relationships with the investment community. "Seth provides a demonstrated track record of proactive, finance-driven leadership in health care investor relations to Evolent," said Evolent Health Chief Financial Officer John Johnson. "He brings long-ter
WASHINGTON, Jan. 13, 2021 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced that Kim A. Keck has been appointed to its Board of Directors, effective immediately and will stand for election at the Company's 2021 annual meeting of stockholders. Ms. Keck has more than 30 years' experience in the health care industry and currently serves as President and Chief Executive Officer of the Blue Cross Blue Shield Association (BCBSA), a national federation of 36 independent, community-based and locally operated Blue Cross and Blue Shield companies that provide health care coverag
Company to Participate in Upcoming Conferences WASHINGTON, Oct. 11, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9
Revenue of $647.1 million, an increase of $178.0 million or 37.9%, from the three months ended June 30, 2023.Net loss attributable to common shareholders of Evolent Health, Inc. of $(6.4) million and a net loss margin of (1.0)%.Adjusted EBITDA of $52.0 million resulting in an Adjusted EBITDA margin of 8.0%.Narrows revenue outlook for full year 2024 and provides updated 2024 Adjusted EBITDA guidance.Reiterates confidence in achieving $300 million in Adjusted EBITDA run rate exiting 2024.WASHINGTON, Aug. 8, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care
Company to Participate in Upcoming Conferences WASHINGTON, July 11, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its second quarter 2024 financial results on Thursday, August 8, 2024, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume BSX PUT SWEEP BEARISH 08/16/24 $75.00 $68.9K 5.5K 2.1K MRNA CALL SWEEP NEUTRAL 11/15/24 $170.00 $121.
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)